ArticleMolecular cancer2026
Genetically driven immune microenvironment states associate with therapeutic responses in MYD88 mutant lymphomas.
Abstract read
In one paragraph
Article in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mouse models of B cell lymphomas on the basis of genetic features.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors.
Jon CelayDepartment of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain.
Miriam RecaldeDepartment of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain.
Maria V RevueltaDivision of Hematology and Oncology, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
Marta LarrayozDepartment of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain.
Carmen VicenteDepartment of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain.
Teresa LozanoProgram of Immunology and Immunotherapy, Center for Applied Medical Research CIMA, University of Navarra, IDISNA, Pamplona, Spain.
Carmen GilDepartment of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain.
Jennifer R ChapmanDepartment of Pathology and Laboratory Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Marcos Garcia-LacarteDepartment of Biochemistry and Genetics, Universidad de Navarra, IDISNA, CIBERONC, Pamplona, Spain.
Carmen GonzalezDepartment of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain.
Beñat AricetaDepartment of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain.
Sara RodriguezDepartment of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain.
Marta LasaDepartment of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain.
Maria J Garcia-BarchinoDepartment of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain.
Vicente FresquetDepartment of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain.
Maddalen JimenezDepartment of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain.
Sonia SanzDepartment of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain.
Ming-Qing DuDivision of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK.
Giovanna RoncadorMonoclonal Antibodies Unit, Spanish National Cancer Research Center CNIO, Biotechnology Program, Madrid, Spain.
Zaira VegaHistopathology Unit, Spanish National Cancer Research Center CNIO, Biotechnology Program, Madrid, Spain.
Antonio SaccoClinical Trial Center, Translational Research and Phase I Unit, ASST Spedali Civil Di Brescia, Brescia, Italy.
Aldo RoccaroClinical Trial Center, Translational Research and Phase I Unit, ASST Spedali Civil Di Brescia, Brescia, Italy.
Gero KnittelDepartment of Hematology and Stem Cell Transplantation, Center for Molecular Biotechnology, University of Duisburg-Essen, Essen, Germany.
Hans Christian ReinhardtDepartment of Hematology and Stem Cell Transplantation, Center for Molecular Biotechnology, University of Duisburg-Essen, Essen, Germany.
Rocco PiazzaDepartment of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
Sylvia HerterRoche Pharma Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.
Rebecca GoodhewCambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.
Jonathan CaronCentre de Recherche Des Cordeliers, INSERM, Université Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Paris, France.
Damien Roos-WeilCentre de Recherche Des Cordeliers, INSERM, Université Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Paris, France.
Jesus San MiguelDepartment of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain.
Miguel CanalesDepartment of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain.
Daniel J HodsonCambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.
Izidore S LossosDivision of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Juan J LasarteProgram of Immunology and Immunotherapy, Center for Applied Medical Research CIMA, University of Navarra, IDISNA, Pamplona, Spain.
Sergio RoaDepartment of Biochemistry and Genetics, Universidad de Navarra, IDISNA, CIBERONC, Pamplona, Spain.
Felipe ProsperDepartment of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain.
Bruno PaivaDepartment of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain.
Leandro CerchiettiDivision of Hematology and Oncology, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA. Leandro.Cerchietti@nyulangone.org.
Jose A Martinez-ClimentDepartment of Hematology, Center for Applied Medical Research, Cancer Center Clinica Univeridad de Navarra, University of Navarra, Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain. jamcliment@unav.es.
Funding
Project 4 Green-DavisP01CA272295 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Leandro C Cerchietti, CHRISTOPHER R FLOWERS · 2024 to 2026
$9.3MRole of the stromal microenvironment in B-cell lymphoma progression and immune escapeR01CA242069 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI CERCHIETTI, LEANDRO C · 2020 to 2024
$2.9MRole of BCL10 somatic mutations in lymphomagenesis and response to BCR-targeted therapiesR01CA249843 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI CERCHIETTI, LEANDRO C · 2020 to 2024
$2.8MNCI NIH HHS P01 CA272295NCI NIH HHS R01 CA242069NCI NIH HHS R01 CA249843Wellcome Trust
Abstract
The interaction between lymphoma cells and immune microenvironment cells and the impact of this functional interplay on therapeutic responses remain largely unexplored. Here, we utilized murine models with oncogenically active MYD88 and additional genetic lesions co-triggered at selected B cell stages to generate human-like lymphomas harboring the MYD88
Indexed as
LymphomaMutationMyeloid Differentiation Factor 88Tumor MicroenvironmentAnimalsCell Line, TumorDisease Models, AnimalHumansImmunotherapyMiceT-LymphocytesMyeloid Differentiation Factor 88Immune evasionImmune microenvironmentImmunotherapyLymphomaMYD88L265P mutationPersonalized medicine
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.